{"apiVersion":"1","query":{"date":"2026-07-14","window":1,"query":"","ticker":"","tickers":[],"category":"all","formType":"all","completeness":"all","includeSparse":false},"meta":{"generatedAt":"2026-07-15T07:40:15.867Z","source":{"mode":"live","provider":"Drillr"},"sourceRowCount":65,"totalFilings":20,"matchedFilings":20,"returnedFilings":20,"limit":100,"truncated":false},"data":{"date":"2026-07-14","fromDate":"2026-07-14","windowDays":1,"fetchedAt":"2026-07-15T07:40:15.867Z","source":{"mode":"live","provider":"Drillr"},"sourceRowCount":65,"filings":[{"accession":"0001104659-26-083326","formType":"8-K","ticker":"NXTC","companyName":"NextCure, Inc.","cik":"1661059","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data/1661059/000110465926083326/0001104659-26-083326-index.html","secAccessible":false,"importanceScore":106.1,"ranking":{"eventClass":72,"disclosedValue":22.1,"multiSection":12,"completeness":0,"total":106.1,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 22.1 points.","7 distinct sections contribute 12 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"7 material disclosures in one filing","primaryAmount":320000000,"currency":"USD","rawRowCount":9,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing agreement · $261M","facts":["NextCure and Avere Therapeutics entered into a merger agreement on July 14, 2026, structured as a two-step triangular merger where Avere will merge into wholly-owned subsidiaries of NextCure.","Post-closing, pre-merger Avere stockholders are expected to own approximately 98.11% of the combined company, and the merger is intended to qualify as a tax-free reorganization.","Concurrently with signing, Avere secured a $320 million private placement of PIPE securities, expected to close immediately prior to the merger.","approximately $320 million — aggregate private placement purchase price.","$250,000,000 — company equity value.","$11,000,000 — parent valuation.","Counterparties: Avere Therapeutics, Inc.."],"amount":261000000,"currency":"USD","itemCode":"5.01","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $320M","facts":["The two-step merger results in Avere becoming a wholly owned subsidiary of NextCure, with pre-Merger Avere stockholders owning ~98.11% of the combined company post-closing.","The merger is intended to qualify as a tax-free reorganization under U.S. tax law.","Upon specified termination, NextCure pays a $330,000 fee and Avere pays a $2,000,000 fee plus up to $750,000 of NextCure's transaction expenses.","Concurrently with the Merger Agreement, investors agreed to purchase an aggregate of $320 million of Avere common stock and pre-funded warrants, with closing immediately prior to the first merger effective time.","A minimum of $150 million in proceeds is required for the merger to close.","Certain NextCure directors and officers holding ~12% of outstanding NextCure common stock agreed to vote their shares in favor of the NextCure Voting Proposals and against any alternative acquisition proposals.","approximately $320 million — total aggregate purchase price."],"amount":320000000,"currency":"USD","itemCode":"1.01","rawRowCount":3},{"id":"deal-3","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing agreement","facts":["NextCure will issue one contingent value right (CVR) per share to pre-Merger NextCure stockholders, entitling holders to 90% of gross proceeds from disposition of NextCure's legacy assets during the CVR term, less permitted deductions.","Counterparties: Rights Agent, NextCure pre-Merger stockholders."],"itemCode":"1.01","rawRowCount":1},{"id":"deal-4","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement","facts":["Certain Avere stockholders holding ~40% of outstanding Avere capital stock agreed to vote their shares in favor of the Merger Agreement and against any alternative acquisition proposals.","Counterparties: certain Avere stockholders holding approximately 40% of outstanding Avere capital stock."],"itemCode":"1.01","rawRowCount":1},{"id":"deal-5","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement","facts":["Certain Avere executive officers, directors and stockholders agreed not to transfer their shares of NextCure common stock for 180 days following the merger closing date.","Counterparties: certain Avere executive officers, directors and stockholders."],"itemCode":"1.01","rawRowCount":1},{"id":"deal-6","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement","facts":["NextCure opted out of continued cost-sharing for the co-developed LNCB74 ADC product candidate under the existing collaboration agreement.","Parties are in discussions regarding potential continuation of the trial by LigaChem as sole developing party.","Counterparties: LigaChem Biosciences, Inc.."],"itemCode":"1.01","rawRowCount":1},{"id":"deal-7","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $1.9M","facts":["NextCure's board approved a restructuring plan to reduce a substantial majority of its workforce pending merger closing, with expected one-time cash charges of ~$1.9 million for severance and related termination costs.","approximately $1.9 million — expected one time charges."],"amount":1900000,"currency":"USD","itemCode":"1.01","rawRowCount":1}]},{"accession":"0001193125-26-302473","formType":"8-K","ticker":"SPRO","companyName":"Spero Therapeutics, Inc.","cik":"1701108","filingDate":"2026-07-14","eventDate":"2026-07-08","secUrl":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/0001193125-26-302473-index.html","secAccessible":false,"importanceScore":103.5,"ranking":{"eventClass":72,"disclosedValue":23.5,"multiSection":8,"completeness":0,"total":103.5,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 23.5 points.","3 distinct sections contribute 8 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"3 material disclosures in one filing","primaryAmount":1085000000,"currency":"USD","rawRowCount":3,"categories":["deal","debt"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Asset transaction · $1.085B","facts":["Spero Therapeutics receives an exclusive, sublicensable license to develop, manufacture and commercialize CD40L-targeting compounds including SP001 (IBI355) worldwide excluding Greater China (Innovent Territory), and grants Innovent an exclusive license for the same assets in Innovent Territory.","Spero is obligated to pay $35 million upfront, up to $1.05 billion in aggregate milestone payments upon achievement of development, regulatory and commercial milestones, plus tiered royalties on annual net sales of licensed products.","Spero must use commercially reasonable efforts to develop and obtain regulatory approval for at least one licensed product in the United States and one major European or Asian market.","$35.0 million — upfront payment.","approximately $1.05 billion — aggregate development regulatory commercial milestone payments.","Counterparties: Innovent Biologics (Suzhou) Co., Ltd., Fortvita Biologics (USA), Inc.."],"amount":1085000000,"currency":"USD","itemCode":"1.01","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $106.575M","facts":["Spero transferred rights to its existing GSK tebipenem HBr license agreement and related milestone/royalty proceeds to wholly-owned special purpose vehicle subsidiaries.","The SPV issued $105 million aggregate principal amount of 10% per annum senior secured notes maturing 9 years after closing, and sold 65% of GSK proceeds remaining after full note repayment to Healthcare Royalty Management affiliates for $1.575 million.","Spero retains 35% of post-note proceeds and provides a limited recourse guaranty of the SPV's obligations.","$105,000,000 — aggregate principal amount of notes.","$1,575,000 — rpa purchase price.","$3,150,000 — original issue discount.","Counterparties: affiliates of Healthcare Royalty Management, LLC."],"amount":106575000,"currency":"USD","itemCode":"1.01","rawRowCount":1},{"id":"debt-1","category":"debt","sourceCategories":["debt"],"sourceTables":["debt_issuance"],"headline":"Debt financing · $105M","facts":["$105,000,000 — principal amount.","10% per annum — interest rate.","$1,575,000 — rpa purchase price.","$3,150,000 — original issue discount."],"amount":105000000,"currency":"USD","itemCode":"2.03","rawRowCount":1}]},{"accession":"0001193125-26-302660","formType":"8-K","ticker":"LGND","companyName":"Ligand Pharmaceuticals Incorporated","cik":"886163","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data/886163/000119312526302660/0001193125-26-302660-index.html","secAccessible":false,"importanceScore":103.1,"ranking":{"eventClass":72,"disclosedValue":23.1,"multiSection":8,"completeness":0,"total":103.1,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 23.1 points.","3 distinct sections contribute 8 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"3 material disclosures in one filing","primaryAmount":739000000,"currency":"USD","rawRowCount":4,"categories":["deal","debt"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Asset transaction · $739M","facts":["Ligand Pharmaceuticals completed its merger/acquisition of XOMA Royalty Corporation on July 14, 2026.","XOMA Royalty stockholders received $39.00 per share in cash plus one contingent value right per share, with a total stated equity value of approximately $739 million.","The transaction adds over 200 biopharmaceutical royalty assets, including seven commercial products, to Ligand's portfolio.","$39.00 per share — price per share.","$125.0 million — revolving credit facility size.","$100 million — minimum trailing four-quarter consolidated ebitda (june 30 2026 to march 31 2027).","Counterparties: XOMA Royalty Corporation."],"amount":739000000,"currency":"USD","itemCode":"2.01","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing conversion · $39","facts":["At the effective time of the merger, each outstanding share of XOMA Royalty common stock was converted into the right to receive $39.00 in cash per share plus a contingent value right (CVR) entitling holders to future contingent payments from a CVR trust.","XOMA Royalty completed a holding company reorganization prior to the merger, with HoldCo surviving the merger as a wholly owned subsidiary of Ligand.","$39.00 per Share — price per share.","Counterparties: XOMA Royalty Corporation, XOMA Royalty Holdings Corporation."],"amount":39,"currency":"USD","itemCode":"1.01","rawRowCount":1},{"id":"deal-3","category":"deal","sourceCategories":["deal","debt"],"sourceTables":["company_deal_events","debt_issuance"],"headline":"Material agreement · $125M","facts":["This amended agreement restates the original October 12, 2023 credit agreement in full, providing for a $125 million revolving credit facility maturing September 12, 2028.","Borrowings are secured by company collateral and guaranteed by the company's material domestic subsidiaries, with financial covenants requiring minimum consolidated EBITDA and a maximum leverage ratio.","Interest is based on either Term SOFR or a base rate plus applicable margins, with a commitment fee on undrawn commitments.","Amends and restates in full the original October 12, 2023 credit agreement, establishing a new $125.0 million revolving credit facility maturing September 12, 2028.","$125.0 million — total revolving commitment.","$100 million — minimum consolidated ebitda.","$150 million — minimum consolidated ebitda.","Amends and restates in its entirety the original October 12, 2023 credit agreement, establishing a new $125.0 million secured revolving credit facility maturing in 2028.","$125.0 million — principal amount.","$100 million — minimum consolidated ebitda period1."],"amount":125000000,"currency":"USD","itemCode":"1.01, 2.03","rawRowCount":2}]},{"accession":"0000811589-26-000149","formType":"8-K","ticker":"FBNC","companyName":"First Bancorp","cik":"811589","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data/811589/000081158926000149/0000811589-26-000149-index.html","secAccessible":false,"importanceScore":97.4,"ranking":{"eventClass":72,"disclosedValue":21.4,"multiSection":4,"completeness":0,"total":97.4,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 21.4 points.","2 distinct sections contribute 4 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Material agreement · $166M","primaryAmount":166000000,"currency":"USD","rawRowCount":4,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $166M","facts":["First Carolina will merge with and into First Bancorp, and its subsidiary bank will merge into First Bancorp's subsidiary bank.","Aggregate merger consideration totals approximately $166 million, with First Carolina shareholders receiving 14.5340 shares of First Bancorp common stock and $294.94 cash per First Carolina share.","Closing is expected in Q4 2026 or Q1 2027, and First Carolina may pay a $6.4 million termination fee to First Bancorp if the agreement is terminated under specified circumstances.","approximately $166 million — total value.","$64.22 per share — price per share.","$294.94 — cash per share.","Counterparties: First Carolina Bancshares Corporation."],"amount":166000000,"currency":"USD","itemCode":"1.01","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement","facts":["Counterparties are required to vote at least 40% of outstanding First Carolina common stock in favor of the merger and against alternative transactions, and are prohibited from transferring their shares prior to shareholder approval.","The agreement terminates no later than July 14, 2028.","The agreement provides for release of all claims held by counterparties against First Carolina, Carolina Bank, their directors, officers and respective successors, effective upon consummation of the merger.","The agreement prohibits counterparties from disclosing confidential information, soliciting customers or employees of the combined company, and engaging in competing business within the restricted territory for a period of two years after merger consummation.","Counterparties: Directors, executive officers and certain shareholders of First Carolina Bancshares Corporation.","Outside or expiry date: 2028-07-14."],"itemCode":"1.01","rawRowCount":3}]},{"accession":"0001079973-26-000947","formType":"8-K","ticker":"BNET","companyName":"BNET","cik":"","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data//000107997326000947/0001079973-26-000947-index.html","secAccessible":false,"importanceScore":96.2,"ranking":{"eventClass":72,"disclosedValue":16.2,"multiSection":8,"completeness":0,"total":96.2,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 16.2 points.","3 distinct sections contribute 8 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"3 material disclosures in one filing","primaryAmount":1774512.72,"currency":"USD","rawRowCount":4,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing conversion · $1.775M","facts":["Resolves all construction-related mechanics liens and litigation between Bion and Hamstra related to the Fair Oaks Ammonia Recovery System project.","All parties agree to dismiss pending claims and release all claims except reserved third-party injury and breach of agreement claims.","Bion issues a $1,774,512.72 convertible promissory note to Hamstra as settlement consideration.","Bion issues this $1,774,512.72 note to Hamstra with 10% annual interest, maturing December 31, 2026, secured by the Fair Oaks project building and equipment.","Upon a qualified financing of at least $2M, Bion pays $653,915 cash, and remaining balance plus interest converts to Bion common stock at the financing price.","Includes piggyback registration rights for converted shares.","$1,774,512.72 — principal amount."],"amount":1774512.72,"currency":"USD","itemCode":"1.01","rawRowCount":2},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing conversion","facts":["Extends the maturity date of all outstanding Bion Secured Convertible Promissory Notes and May 2024 Convertible Promissory Notes from the original June 30, 2026 date to December 31, 2026.","All other terms of the notes remain unchanged.","Extended maturity date from June 30, 2026 to December 31, 2026, all other terms unchanged","Outside or expiry date: 2026-12-31."],"itemCode":"1.01","rawRowCount":1},{"id":"deal-3","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing conversion","facts":["Extends the maturity date of the Bion Loan Group's outstanding Secured Convertible Promissory Note from the original June 30, 2026 date to January 31, 2027.","All other terms of the note remain unchanged.","Extended maturity date from June 30, 2026 to January 31, 2027, all other terms unchanged","Counterparties: Bion Loan Group.","Outside or expiry date: 2027-01-31."],"itemCode":"1.01","rawRowCount":1}]},{"accession":"0001726978-26-000051","formType":"8-K","ticker":"GSHD","companyName":"Goosehead Insurance, Inc","cik":"1726978","filingDate":"2026-07-14","eventDate":"2026-07-08","secUrl":"https://www.sec.gov/Archives/edgar/data/1726978/000172697826000051/0001726978-26-000051-index.html","secAccessible":false,"importanceScore":96,"ranking":{"eventClass":72,"disclosedValue":20,"multiSection":4,"completeness":0,"total":96,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 20 points.","2 distinct sections contribute 4 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Material agreement · $50M","primaryAmount":50000000,"currency":"USD","rawRowCount":2,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement","facts":["This settlement resolves the litigation Mickey Dollens v.","Goosehead Insurance, Inc. pending in the Delaware Court of Chancery.","The Company entered into the settlement to avoid ongoing litigation expenses and distraction of management time, and it requires the Company to amend its 2018 original Stockholders Agreement per the settlement terms.","Counterparties: Mickey Dollens."],"itemCode":"1.01","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $50M","facts":["This agreement amends and restates the original May 1, 2018 Stockholders Agreement to implement the court-approved settlement.","As long as the Pre-IPO Holders collectively hold at least 10% of the Company's outstanding common stock, they have approval rights for specified major corporate actions and the right to designate a majority of the Company's board of directors.","Amends and restates the original May 1, 2018 Stockholders Agreement; removes provisions required to be eliminated by the settlement, adds approval rights for major corporate actions and board nomination rights for Pre-IPO Holders that apply while they meet the 10% aggregate ownership requirement.","$50 million — equity issuance approval threshold.","$.01 per share — class a common stock par value.","$0.01 per share — class b common stock par value.","Counterparties: Mark E. Jones, Robyn Jones, The Mark and Robyn Jones Descendants Trust 2014, The Lanni Elaine Romney Family Trust 2014, The Lindy Jean Langston Family Trust 2014, The Camille LaVaun Peterson Family Trust 2014, The Desiree Robyn Coleman Family Trust 2014, The Adrienne Morgan Jones Family Trust 2014, The Mark Evan Jones, Jr. Family Trust 2014, Serena Jones, Lanni Romney, Lindy Langston, Camille Peterson, Desiree Coleman, Adrienne (Jones) Kebodeaux, Mark E. Jones, Jr., Texas Wasatch Insurance Partners, L.P.."],"amount":50000000,"currency":"USD","itemCode":"1.01","rawRowCount":1}]},{"accession":"0001193125-26-302584","formType":"8-K","ticker":"DIOD","companyName":"Diodes Incorporated","cik":"29002","filingDate":"2026-07-14","eventDate":"2026-07-10","secUrl":"https://www.sec.gov/Archives/edgar/data/29002/000119312526302584/0001193125-26-302584-index.html","secAccessible":false,"importanceScore":94,"ranking":{"eventClass":72,"disclosedValue":22,"multiSection":0,"completeness":0,"total":94,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 22 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Asset transaction · $300M","primaryAmount":300000000,"currency":"USD","rawRowCount":1,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Asset transaction · $300M","facts":["Pursuant to the Merger Agreement, Diodes' wholly owned subsidiary GN Merger Sub Inc. will merge with and into Elevate Semiconductor, Inc., with Elevate surviving as a wholly owned subsidiary of Diodes.","The aggregate merger consideration has a $250.0 million base purchase price, subject to customary adjustments for cash, indebtedness, and working capital, with potential additional earnout payments of up to $50.0 million in aggregate based on achievement of specified 2027-2030 revenue and gross margin targets.","All outstanding Elevate common shares and vested in-the-money options will be converted to cash consideration, while unvested options are canceled for no consideration.","$250.0 million — base purchase price.","$50.0 million — potential aggregate earnout.","$300.0 million — total maximum consideration.","Counterparties: Elevate Semiconductor, Inc., Presidio Investors ELV Continuation GP, LLC."],"amount":300000000,"currency":"USD","itemCode":"1.01","rawRowCount":1}]},{"accession":"0001104659-26-083274","formType":"8-K","ticker":"ANRO","companyName":"Alto Neuroscience, Inc.","cik":"1999480","filingDate":"2026-07-14","eventDate":"2026-07-13","secUrl":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926083274/0001104659-26-083274-index.html","secAccessible":false,"importanceScore":92.8,"ranking":{"eventClass":72,"disclosedValue":20.8,"multiSection":0,"completeness":0,"total":92.8,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 20.8 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Financing agreement · $100M","primaryAmount":100000025,"currency":"USD","rawRowCount":1,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing agreement · $100M","facts":["Alto Neuroscience agreed to issue and sell 3,776,436 shares of its common stock at an offering price of $26.48 per share.","The company estimates net proceeds of approximately $93.9 million after deducting underwriting discounts, commissions, and estimated offering expenses.","Net proceeds are intended to fund clinical development of ALTO-207 and general working capital, with closing expected on July 14, 2026.","3,776,436 shares at $26.48 per share — total value.","approximately $93.9 million — net proceeds.","$26.48 per share — price per share.","Counterparties: BofA Securities, Inc., Stifel, Nicolaus & Company, Incorporated, William Blair & Company, L.L.C., Robert W. Baird & Co. Incorporated, JonesTrading Institutional Services LLC, H.C. Wainwright & CO., LLC."],"amount":100000025,"currency":"USD","itemCode":"1.01","rawRowCount":1}]},{"accession":"0001171843-26-004612","formType":"8-K","ticker":"PAC","companyName":"Grupo Aeroportuario del Pacífico, S.A.B. de C.V.","cik":"1347557","filingDate":"2026-07-14","eventDate":"2026-05-01","secUrl":"https://www.sec.gov/Archives/edgar/data/1347557/000117184326004612/0001171843-26-004612-index.html","secAccessible":false,"importanceScore":92,"ranking":{"eventClass":72,"disclosedValue":20,"multiSection":0,"completeness":0,"total":92,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 20 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Material agreement · $50M","primaryAmount":50000000,"currency":"USD","rawRowCount":1,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $50M","facts":["This transaction combines Cross Border Xpress (CBX) operations into Grupo Aeroportuario del Pacífico (GAP) via merger, and includes the completed acquisition of the remaining 25% equity interest in CBX, giving GAP 100% ownership.","The merger was approved by shareholders in December 2025, signed April 30, 2026, and closed effective May 1, 2026.","GAP issued 89,740,731 new net shares as consideration, and the deal included acquisition of OTV land for $50 million USD.","Fair value measurements for the transaction remain preliminary.","US$50.0 million — otv land acquisition price.","Ps. 935.0 million — otv land acquisition price (mxn equivalent).","Ps. 5,427.1 million — increase in cash and cash equivalents from business combination."],"amount":50000000,"currency":"USD","itemCode":"2.01","rawRowCount":1}]},{"accession":"0001849867-26-000014","formType":"8-K","ticker":"CLST","companyName":"Catalyst Bancorp, Inc.","cik":"1849867","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data/1849867/000184986726000014/0001849867-26-000014-index.html","secAccessible":false,"importanceScore":91.8,"ranking":{"eventClass":72,"disclosedValue":19.8,"multiSection":0,"completeness":0,"total":91.8,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 19.8 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Material agreement · $41.1M","primaryAmount":41100000,"currency":"USD","rawRowCount":1,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $41.1M","facts":["Catalyst Bancorp completed the acquisition of Lakeside Bancshares and its wholly-owned subsidiary Lakeside Bank on July 14, 2026, under a merger agreement dated April 7, 2026.","Lakeside shareholders received $19.58 per share in cash for all outstanding shares, for an aggregate transaction value of $41.1 million.","After the share exchange, Lakeside Bancshares merged into Catalyst Bancorp and Lakeside Bank merged into Catalyst Bank.","$19.58 per share — price per share.","$41.1 million aggregate — total transaction value.","$375.7 million — lakeside bank total assets as of march 31, 2026.","Counterparties: Lakeside Bancshares, Inc., Lakeside Bank."],"amount":41100000,"currency":"USD","itemCode":"2.01","rawRowCount":1}]},{"accession":"0001213900-26-077736","formType":"8-K","ticker":"PLAG","companyName":"PLAG","cik":"","filingDate":"2026-07-14","eventDate":"2026-07-13","secUrl":"https://www.sec.gov/Archives/edgar/data//000121390026077736/0001213900-26-077736-index.html","secAccessible":false,"importanceScore":90.1,"ranking":{"eventClass":72,"disclosedValue":18.1,"multiSection":0,"completeness":0,"total":90.1,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 18.1 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Financing agreement · $8.923M","primaryAmount":8922860,"currency":"USD","rawRowCount":1,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing agreement · $8.923M","facts":["Planet Green Holdings Corp. may sell up to approximately $8,922,860 of its common stock from time to time through Curvature Securities LLC, acting as its sole sales agent or principal.","Sales will be conducted as at-the-market offerings, primarily on the NYSE American exchange, and the Company is not obligated to sell any shares under the agreement.","Curvature Securities will receive a 3% commission on gross proceeds of any completed sales and receives customary indemnification from the Company.","approximately $8,922,860 — total value.","$2.30 — price per share.","approximately $26.8 million — public float.","Counterparties: Curvature Securities, LLC."],"amount":8922860,"currency":"USD","itemCode":"1.01","rawRowCount":1}]},{"accession":"0001193125-26-302648","formType":"8-K","ticker":"XOMAP","companyName":"XOMA Corporation","cik":"791908","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data/791908/000119312526302648/0001193125-26-302648-index.html","secAccessible":false,"importanceScore":88.1,"ranking":{"eventClass":72,"disclosedValue":4.1,"multiSection":12,"completeness":0,"total":88.1,"reasons":["Deal event class contributes 72 points.","A disclosed monetary value contributes 4.1 points.","5 distinct sections contribute 12 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"5 material disclosures in one filing","primaryAmount":39,"currency":"USD","rawRowCount":15,"categories":["deal","executive"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Agreement terminated or converted","facts":["The loan agreement was between borrower XRL 1 LLC (a wholly owned subsidiary of the filer), lender parties, and Blue Owl Capital Corporation as administrative agent.","It was terminated July 14 2026, with all outstanding obligations paid off in full.","Counterparties: the Lenders, Blue Owl Capital Corporation."],"itemCode":"1.02","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing conversion · $39","facts":["Original merger agreement dated April 27 2026; post-amendment terms provide each outstanding common share converts to $39.00 cash plus contingent value rights, with preferred shares redeemed prior to closing.","No specific changes to terms disclosed in the provided document","On July 14 2026, the merger was consummated.","Each outstanding common share (excluding canceled and dissenting shares) receives $39.00 cash plus contingent value rights from a CVR trust.","All preferred shares were redeemed for accrued unpaid dividends.","$39.00 per Share — price per share.","Counterparties: Ligand Pharmaceuticals Incorporated, Flex Merger Sub, Inc., XOMA Royalty Holdings Corporation."],"amount":39,"currency":"USD","itemCode":"1.02","rawRowCount":2},{"id":"deal-3","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $39","facts":["Ligand Pharmaceuticals completed the acquisition of XOMA Royalty via a triangular merger that closed on July 14, 2026.","XOMA Royalty common stockholders receive $39.00 per share in cash plus one non-transferable contingent value right (CVR) per share, entitling holders to a portion of 75% of net proceeds from certain pending XOMA Royalty litigation.","Following closing, XOMA Royalty common stock was delisted from the Nasdaq Global Market.","$39.00 per share — price per share common stock.","$0.0075 par value per share — par value common stock.","$0.05 par value per share — par value series a preferred stock.","Counterparties: Ligand Pharmaceuticals Incorporated."],"amount":39,"currency":"USD","itemCode":"2.01","rawRowCount":1},{"id":"deal-4","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Material agreement · $39","facts":["Ligand Pharmaceuticals completed the acquisition of XOMA Royalty, which closed on July 14, 2026.","XOMA Royalty common stockholders receive $39.00 cash per share plus one non-transferable contingent value right per share, entitling holders to a portion of 75% of net proceeds from certain pending litigation at XOMA Royalty.","Following closing, XOMA Royalty common stock was delisted from the Nasdaq Global Market.","$39.00 per share — price per share.","Counterparties: Ligand Pharmaceuticals Incorporated."],"amount":39,"currency":"USD","itemCode":"5.01","rawRowCount":1},{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Director of the Company transition","facts":["Jack L. Wyszomierski departed as Director of the Company. Reason: resignation.","Heather L. Franklin departed as Director of the Company. Reason: resignation.","Natasha Hernday departed as Director of the Company. Reason: resignation.","Owen Hughes departed as Director of the Company. Reason: resignation.","Barbara Kosacz departed as Director of the Company. Reason: resignation.","Joseph M. Limber departed as Director of the Company. Reason: resignation.","Matthew Perry departed as Director of the Company. Reason: resignation.","Todd C. Davis was appointed as Director of the Company, effective 2026-07-14.","Octavio Espinoza was appointed as Director of the Company, effective 2026-07-14.","Andrew Reardon was appointed as Director of the Company, effective 2026-07-14."],"itemCode":"5.02","rawRowCount":10}]},{"accession":"0001193125-26-302638","formType":"8-K","ticker":"FLYX","companyName":"FLYX","cik":"","filingDate":"2026-07-14","eventDate":"2026-07-13","secUrl":"https://www.sec.gov/Archives/edgar/data//000119312526302638/0001193125-26-302638-index.html","secAccessible":false,"importanceScore":76,"ranking":{"eventClass":72,"disclosedValue":0,"multiSection":4,"completeness":0,"total":76,"reasons":["Deal event class contributes 72 points.","2 distinct sections contribute 4 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Asset transaction · $0.001","primaryAmount":0.001,"currency":"USD","rawRowCount":3,"categories":["deal"],"sections":[{"id":"deal-1","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Asset transaction · $0.001","facts":["flyExclusive completed the acquisition of Jet.AI's aviation assets via a triangular merger with Jet.AI's wholly-owned subsidiary SpinCo.","All consideration for the transaction consists of shares of flyExclusive Class A common stock.","Acquired assets include Jet.AI's jet card customers, three aircraft, deposits for future aircraft delivery positions, marketable securities, and cash.","$0.001 per share — par value per share of spinco common stock.","$0.0001 per share — par value per share of flyexclusive class a common stock.","Approximately $4.1 million — value of deposit for three future citation cj3 delivery positions.","Counterparties: Jet.AI Inc.."],"amount":0.001,"currency":"USD","itemCode":"2.01","rawRowCount":1},{"id":"deal-2","category":"deal","sourceCategories":["deal"],"sourceTables":["company_deal_events"],"headline":"Financing conversion","facts":["This amendment amends the existing Amended and Restated Agreement and Plan of Merger between the parties.","It modifies the post-closing net cash adjustment mechanism, specifically establishing new rules for valuing SpinCo's indirect equity investment in Space Exploration Technologies Corporation for net cash calculation purposes.","Added new valuation rules for SpinCo's indirect equity investment in Space Exploration Technologies Corporation for post-closing net cash adjustment, covering deficit net liquidation proceeds, surplus net liquidation proceeds, and no liquidation scenarios, plus added related definitions to the original merger agreement.","FlyX Merger Sub (wholly owned subsidiary of flyExclusive) merged with and into SpinCo, with SpinCo surviving as a wholly owned subsidiary of flyExclusive.","Each outstanding share of SpinCo common stock converts to 3.6253 shares of flyExclusive Class A common stock, with an aggregate of 7,096,117 shares issuable, 20% reserved pending final post-closing net cash adjustment.","Counterparties: Jet.AI Inc., Jet.AI SpinCo, Inc.."],"itemCode":"1.01","rawRowCount":2}]},{"accession":"0001104659-26-083237","formType":null,"ticker":"CODQL","companyName":"CODQL","cik":"","filingDate":"2026-07-14","eventDate":"2026-07-13","secUrl":"https://www.sec.gov/Archives/edgar/data//000110465926083237/0001104659-26-083237-index.html","secAccessible":false,"importanceScore":66,"ranking":{"eventClass":66,"disclosedValue":0,"multiSection":0,"completeness":0,"total":66,"reasons":["Executive event class contributes 66 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"Chief Executive Officer and Managing Director transition","rawRowCount":4,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Chief Executive Officer and Managing Director transition","facts":["Barend (Barrie) J. van der Merwe was promoted as Chief Executive Officer and Managing Director, effective 2026-08-01.","Garold Spindler departed as Interim Chief Executive Officer. Reason: resignation.","Garold Spindler was appointed as Non-Executive Director, effective 2026-08-01.","Sandeep Deoji was appointed as Interim Chief Financial Officer on an interim basis, effective 2026-08-01."],"itemCode":"5.02","rawRowCount":4}]},{"accession":"0001101215-26-000065","formType":null,"ticker":"BFH","companyName":"Bread Financial Holdings, Inc.","cik":"1101215","filingDate":"2026-07-14","eventDate":"2026-07-08","secUrl":"https://www.sec.gov/Archives/edgar/data/1101215/000110121526000065/0001101215-26-000065-index.html","secAccessible":false,"importanceScore":61,"ranking":{"eventClass":66,"disclosedValue":0,"multiSection":0,"completeness":-5,"total":61,"reasons":["Executive event class contributes 66 points.","Partial extraction applies a 5 point penalty."]},"completeness":"partial","headline":"Executive Vice President and Chief Commercial Officer transition","rawRowCount":2,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Executive Vice President and Chief Commercial Officer transition","facts":["Valerie Greer departed as Executive Vice President and Chief Commercial Officer. Reason: retirement.","Dennis McCarthy was promoted as Executive Vice President and Chief Revenue Officer."],"itemCode":"5.02","rawRowCount":2}]},{"accession":"0001213900-26-077680","formType":null,"ticker":"RMCF","companyName":"Rocky Mountain Chocolate Factory, Inc.","cik":"1616262","filingDate":"2026-07-14","eventDate":"2026-06-29","secUrl":"https://www.sec.gov/Archives/edgar/data/1616262/000121390026077680/0001213900-26-077680-index.html","secAccessible":false,"importanceScore":61,"ranking":{"eventClass":66,"disclosedValue":0,"multiSection":0,"completeness":-5,"total":61,"reasons":["Executive event class contributes 66 points.","Partial extraction applies a 5 point penalty."]},"completeness":"partial","headline":"Interim Chief Executive Officer and Principal Executive Officer named","rawRowCount":1,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Interim Chief Executive Officer and Principal Executive Officer named","facts":["Allen C. Harper was appointed as Interim Chief Executive Officer and Principal Executive Officer on an interim basis, effective 2026-06-30."],"itemCode":"5.02","rawRowCount":1}]},{"accession":"0001213900-26-077784","formType":null,"ticker":"SSII","companyName":"SS Innovations International, Inc.","cik":"1676163","filingDate":"2026-07-14","eventDate":"2026-07-14","secUrl":"https://www.sec.gov/Archives/edgar/data/1676163/000121390026077784/0001213900-26-077784-index.html","secAccessible":false,"importanceScore":61,"ranking":{"eventClass":66,"disclosedValue":0,"multiSection":0,"completeness":-5,"total":61,"reasons":["Executive event class contributes 66 points.","Partial extraction applies a 5 point penalty."]},"completeness":"partial","headline":"Chief Financial Officer named","rawRowCount":1,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Chief Financial Officer named","facts":["Sarah M. Romano was appointed as Chief Financial Officer, effective 2026-08-03."],"itemCode":"5.02","rawRowCount":1}]},{"accession":"0001140361-26-028370","formType":null,"ticker":"SUIG","companyName":"SUI Group Holdings Limited","cik":"1425355","filingDate":"2026-07-14","eventDate":"2026-07-08","secUrl":"https://www.sec.gov/Archives/edgar/data/1425355/000114036126028370/0001140361-26-028370-index.html","secAccessible":false,"importanceScore":61,"ranking":{"eventClass":66,"disclosedValue":0,"multiSection":0,"completeness":-5,"total":61,"reasons":["Executive event class contributes 66 points.","Partial extraction applies a 5 point penalty."]},"completeness":"partial","headline":"Chief Investment Officer departure","rawRowCount":1,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Chief Investment Officer departure","facts":["Stephen Mackintosh departed as Chief Investment Officer. Reason: resignation."],"itemCode":"5.02","rawRowCount":1}]},{"accession":"0001493152-26-033115","formType":null,"ticker":"CINGW","companyName":"Cingulate Inc.","cik":"1862150","filingDate":"2026-07-14","eventDate":"2026-07-09","secUrl":"https://www.sec.gov/Archives/edgar/data/1862150/000149315226033115/0001493152-26-033115-index.html","secAccessible":false,"importanceScore":48,"ranking":{"eventClass":48,"disclosedValue":0,"multiSection":0,"completeness":0,"total":48,"reasons":["Executive event class contributes 48 points.","Complete structured terms receive no penalty."]},"completeness":"complete","headline":"6 directors elected","rawRowCount":6,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"6 directors elected","facts":["Jeff Hargroves was elected as Class II Director, effective 2026-07-09.","Shane J. Schaffer was promoted as Chief Executive Officer, chairman of the Board of Directors, effective 2026-07-09.","Jeff Hargroves was appointed as lead independent director of the Board of Directors, effective 2026-07-09.","Zhanpeng \"Frederick\" Jiang was appointed as chairman of the Audit Committee of the Board of Directors, effective 2026-07-09.","Jeff Hargroves was appointed as chairman of the Nominating and Corporate Governance Committee of the Board of Directors, effective 2026-07-09.","Bryan Lawrence was appointed as chairman of the Compensation Committee of the Board of Directors, effective 2026-07-09."],"itemCode":"5.02","rawRowCount":6}]},{"accession":"0000943374-26-000266","formType":null,"ticker":"CPBI","companyName":"Central Plains Bancshares, Inc. Common Stock","cik":"1979332","filingDate":"2026-07-14","eventDate":"2026-07-08","secUrl":"https://www.sec.gov/Archives/edgar/data/1979332/000094337426000266/0000943374-26-000266-index.html","secAccessible":false,"importanceScore":43,"ranking":{"eventClass":48,"disclosedValue":0,"multiSection":0,"completeness":-5,"total":43,"reasons":["Executive event class contributes 48 points.","Partial extraction applies a 5 point penalty."]},"completeness":"partial","headline":"Leadership change","rawRowCount":1,"categories":["executive"],"sections":[{"id":"executive-1","category":"executive","sourceCategories":["executive"],"sourceTables":["executive_change"],"headline":"Leadership change","facts":["Bradley M. Kool: Compensation Change — Executive Vice President and Chief Financial Officer, effective 2026-07-08."],"itemCode":"5.02","rawRowCount":1}]}],"stats":{"filings":20,"deal":13,"executive":8,"debt":2,"offering":0,"complete":15,"sparse":0,"returned":20}}}